EDX/20/1154
Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
EDX/20/1154
Date of prep: December 2020
Prescribing information and
adverse events reporting
For healthcare professionals only
In response to the following article:
Dear PIP Editor,
There is not enough regulation around over the counter codeine and sales are too frequent. Codeine sales should be suitably counselled and monitored.
I think, however, that codeine should be sold as a cough remedy but with tighter restrictions. In an internet pharmacy, I have previously worked in, every sale is reviewed and checked against a database of customer information to ensure patients are not making multiple purchases. Identification is also checked. This reduces the risk of abuse or misuse.
If community pharmacies followed suit, or if there was a system nationally to support this process then this effective cough remedy could be sold safely.
Too many pharmacies sell opiates without effective counselling. In many pharmacies where I have locumed, the staff are accustomed to selling opiates dozens of times a day without advising the patient of the risk of addiction or even questioning if the product is necessary.
I do not agree with restricting opiates to prescription supply only. Making these products prescription-only would only cause an increased burden on the NHS.
GPs are already pestered into prescribing by patient’s who feel entitled to products readily available over the counter.
It is obvious to me that POM status does not solve these issues.
Yours etc.
Anonymous.
The PIP team would love to know your views on over the counter opiates. Answer the questions below and with your permission, we will publish your response to this story as a letter to the editor.
Pharmacy in Practice is a UK pharmacy publication with its roots in Scotland.
This site is for healthcare professionals, please confirm you are a healthcare professional to continue.
Begin the discussion right here